Watson receives FDA approval for generic Kadian ANDA

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian®. Watson began shipping the product today. Kadian® is indicated to manage moderate to severe pain that continues around-the-clock and is expected to last for an extended period of time.

For the most recent twelve months ending September 30, 2011, Kadian® had sales of approximately $275 million, according to IMS Health data.